Healthcare
Sanofi(SNY)
Live Price
Offline$42.38
-0.28% today
1Y Change
-10.83%
Window
Jun 23, 2025 โ Jun 1, 2026
- Market Cap
- $96.03B
- Revenue Growth
- +5.5%
- EPS Growth
- -7.7%
- Dividend Yield
- 4.9%
Coverage: 236 bars ยท Jun 23, 2025 โ Jun 1, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Sanofi (SNY) is a Healthcare stock with a market cap of $96.03B and listed on NASDAQ. The stock last traded around $42.38 and down 10.8% across the available one-year price window (Jun 23, 2025 โ Jun 1, 2026). Baseline metrics include revenue growth of +5.5%, EPS growth of -7.7%, a dividend yield of 4.9%. What stands out right now is revenue +5.5%, EPS -7.7%, free cash flow +51.1% with operating margin 25.1% and ROIC 11.7%. The dividend matters to the case here, with a current yield around 4.9%. Valuation is more restrained than many high-expectation growth names at P/E 9.3 and price/sales 1.6. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines SNY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+5.5% vs +7.6% peer median
Operating Margin
Above sector median
+25.1% vs +19.4% peer median
P/E
Below sector median
9.3 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 23, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +5.5% and EPS is at -7.7%, with operating margin around 25.1%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 4.9%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -0.4% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 23, 2026 | โ | -1.6% | -2.0% | -5.5% |
2026 Jan 29, 2026 | +6.0% | +1.8% | +2.8% | +5.3% |
2025 Oct 24, 2025 | +6.3% | -0.4% | -2.1% | -3.9% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SNY
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SNY Max Drawdown
-18.95%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SNY and SPY.
Company Overview
Sanofi
NASDAQ Global Select
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
- Leadership
- Olivier Charmeil
- IPO Date
- Jul 1, 2002
- Employees
- 82.9k
- Street Address
- 54, Rue La BoEtie
- Mailing
- Paris, 75008
- Region
- Paris, FR
- Reporting Currency
- USD
- Investor Line
- 33 1 53 77 40 00
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 9.3
- EV/EBITDA
- 10.2
- Price/Sales
- 1.6
- Price/Book
- 1.3
Growth
- Revenue
- +5.5%
- EPS
- -7.7%
- Free Cash Flow
- +51.1%
Profitability
- Gross Margin
- 71.6%
- Operating Margin
- 25.1%
- Net Margin
- 17.6%
- ROE
- 14.4%
- ROIC
- 11.7%
Balance Sheet
- Debt/Equity
- 0.27
- Current Ratio
- 1.01
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.